NDAORALCAPSULE
Approved
Feb 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TETREX is an oral tetracycline phosphate complex capsule, a broad-spectrum antibiotic approved in 1957. It treats bacterial infections across multiple therapeutic areas by inhibiting bacterial protein synthesis. Tetracyclines remain foundational antimicrobials in clinical practice despite their age.
LOE Approaching
This legacy product faces declining exclusivity with moderate competitive pressure (30), suggesting smaller brand teams focused on maintaining market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TETREX offers limited career growth due to its LOE-approaching lifecycle and minimal linked job openings (0). Positions focus on defending market share, managing generic competition, and ensuring supply chain continuity rather than innovation or expansion.
Brand ManagerMedical Science Liaison
Worked on TETREX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.